Braveheart Bio closed a major financing and surfaced in multiple venture updates as new biotech launches attracted investor capital. Braveheart secured $185 million to advance a cardiometabolic program toward Phase 3 in obstructive hypertrophic cardiomyopathy, while VCs also backed newly launched firms Azalea and Neok in a broader financing round recapped by industry press. The flurry of venture activity underscores continued investor appetite for differentiated cardiometabolic and in vivo gene‑engineering approaches despite broader market volatility; execution risk will hinge on IND timelines, clinical readouts and platform differentiation.